{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:38:44Z","timestamp":1793831924262,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100016619","name":"MyoKardia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jacc.2021.09.1381","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T15:15:29Z","timestamp":1639408529000},"page":"2518-2532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":197,"title":["Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"78","author":[{"given":"Sheila M.","family":"Hegde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif F.","family":"Nagueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zemanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna R.","family":"Zwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Y.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Sehnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore P.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.09.1381_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"issue":"25","key":"10.1016\/j.jacc.2021.09.1381_bib2","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.09.1381_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.09.1381_bib4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.09.1381_bib5","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.09.1381_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1573403X1201160126125403","article-title":"Drug therapy for hypertrophic cardiomyopathy: physiology and practice","volume":"12","author":"Sherrid","year":"2016","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.jacc.2021.09.1381_bib7","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ejhf.541","article-title":"Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives","volume":"18","author":"Ammirati","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.09.1381_bib8","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In\u00a0vitro and in\u00a0vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jacc.2021.09.1381_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A\u00a0small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jacc.2021.09.1381_bib10","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A\u00a0small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2021.09.1381_bib11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2021.09.1381_bib12","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.09.1381_bib13","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.09.1381_bib14","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM CMR substudy analysis","volume":"143","author":"Saberi","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacc.2021.09.1381_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic cardiomyopathy","volume":"13","author":"Ho","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.09.1381_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2021.09.1381_bib17","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","article-title":"B-type natriuretic peptide and survival in hypertrophic cardiomyopathy","volume":"61","author":"Geske","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.09.1381_bib18","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/eht070","article-title":"Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy","volume":"34","author":"Coats","year":"2013","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2021.09.1381_bib19","first-page":"A20593","article-title":"Abstract 20593: In\u00a0vivo cardiac effects of mavacamten (MYK-461): evidence for negative inotropy and improved compliance (abstr)","volume":"136","author":"del Rio","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.09.1381_bib20","first-page":"A13204","volume":"138","author":"del Rio","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacc.2021.09.1381_bib21","doi-asserted-by":"crossref","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","article-title":"Mavacamten Decreases Maximal Force and Ca(2+)-sensitivity in the N47K-Myosin Regulatory Light Chain Mouse Model of Hypertrophic Cardiomyopathy","volume":"320","author":"Awinda","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2021.09.1381_bib22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ejhf.971","article-title":"Non-invasive assessment of left ventricular filling pressure","volume":"20","author":"Nagueh","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2021.09.1381_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004052","article-title":"Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation","volume":"10","author":"Debonnaire","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2021.09.1381_bib24","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/echo.13857","article-title":"E\/e' ratio and left atrial area are predictors of atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"35","author":"Costabel","year":"2018","journal-title":"Echocardiography"},{"key":"10.1016\/j.jacc.2021.09.1381_bib25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1253\/circj.71.897","article-title":"Clinical significance of tissue Doppler imaging in patients with hypertrophic cardiomyopathy","volume":"71","author":"Efthimiadis","year":"2007","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2021.09.1381_bib26","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1111\/echo.14539","article-title":"Prognostic significance of left ventricular end diastolic pressure using E\/E' in patients with hypertrophic cardiomyopathy","volume":"36","author":"Badran","year":"2019","journal-title":"Echocardiography"},{"key":"10.1016\/j.jacc.2021.09.1381_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/ehjci\/jex134","article-title":"E\/e' ratio and outcome prediction in hypertrophic cardiomyopathy: the influence of outflow tract obstruction","volume":"19","author":"Lu","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2021.09.1381_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2021.09.1381_bib29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/echo.13158","article-title":"Impact of Septal Reduction on Left Atrial Size and Diastole in Hypertrophic Cardiomyopathy","volume":"33","author":"Finocchiaro","year":"2016","journal-title":"Echocardiography"},{"key":"10.1016\/j.jacc.2021.09.1381_bib30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.echo.2013.05.012","article-title":"Myocardial mechanical remodeling after septal myectomy for severe obstructive hypertrophic cardiomyopathy","volume":"26","author":"Moravsky","year":"2013","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2021.09.1381_bib31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2459\/JCM.0b013e3283383355","article-title":"The progression of left ventricular systolic and diastolic dysfunctions in hypertrophic cardiomyopathy: clinical and prognostic significance","volume":"11","author":"Pinamonti","year":"2010","journal-title":"J\u00a0Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.jacc.2021.09.1381_bib32","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.amjcard.2006.05.013","article-title":"Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy)","volume":"98","author":"Nistri","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2021.09.1381_bib33","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.echo.2009.09.016","article-title":"Left atrial volume index: a predictor of adverse outcome in patients with hypertrophic cardiomyopathy","volume":"22","author":"Yang","year":"2009","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2021.09.1381_bib34","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy.","volume":"75","author":"Ho","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.09.1381_bib35","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10554-016-0858-4","article-title":"Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography","volume":"32","author":"Corona-Villalobos","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2021.09.1381_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5603\/KP.a2018.0242","article-title":"Reduction of left ventricular mass, left atrial size, and N-terminal pro-B-type natriuretic peptide level following alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy","volume":"77","author":"Dabrowski","year":"2019","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.jacc.2021.09.1381_bib37","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.09.1381_bib38","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2021.09.1381_bib39","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/01.CIR.99.3.344","article-title":"Changes in left ventricular diastolic function 6\u00a0months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy","volume":"99","author":"Nagueh","year":"1999","journal-title":"Circulation"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721079006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721079006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:47:20Z","timestamp":1760017640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721079006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":39,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0735109721079006"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.09.1381","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.09.1381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}